About
Matthew Scholz is a Seattle-area biotechnology entrepreneur and computer scientist best known as co-founder and CEO of Oisín Biotechnologies, a company developing genetic medicines for age-related diseases. He previously founded Immusoft and later co-founded Oisín's oncology spinout OncoSenX, where he also serves as CEO and Chairman. Public sources also place him in mentorship and speaker roles across the longevity ecosystem, including LongX and the Longevity Biotech Fellowship.
Areas of interest
longevitybiotechgene therapygenetic medicinecellular senescencesenolyticsimmunotherapycancer therapeuticssarcopeniaaging biologyLNP delivery platformssynthetic biology